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Background: Recently, non-herpetic acute limbic encephalitis (NHALE) was identiﬁed as a new subgroup
of limbic encephalitis. The immunological pathophysiology of NHALE is still unclear. Methods: We mea-
sured the concentrations of interferon-c (IFN-c), tumor necrosis factor-a (TNF-a), interleukin-2 (IL-2), IL-
4, IL-6, IL-10, and soluble TNF receptor 1 (sTNFR1) in the cerebrospinal ﬂuid (CSF) of 15 patients with
NHALE and 13 with herpes simplex encephalitis (HSE) by cytometric bead array or ELISA. Results: The
CSF concentrations of IL-6 in patients with NHALE and IFN-c, IL-6, IL-10, and sTNFR1 in HSE patients were
signiﬁcantly higher than those of controls (p < 0.001, p = 0.004, p < 0.001, p = 0.018, and p < 0.001, respec-
tively). There were signiﬁcant correlations among CSF IL-6, IL-10, and sTNFR1 levels in HSE patients. The
CSF concentrations of IFN-c and sTNFR1 levels of patients with HSE were signiﬁcantly higher than those
with NHALE (p = 0.001 and p = 0.002, respectively). Conclusions: CSF cytokine levels in NHALE were rela-
tively low compared with those in HSE. These results may be related to the favorable prognosis of NHALE.
 2008 Elsevier Ltd. All rights reserved.1. Introduction
In Japan, non-herpetic acute limbic encephalitis (NHALE) was
identiﬁed as a new subgroup of limbic encephalitis [1–3]. The clin-
ical picture of NHALE is similar to that of herpes simplex enceph-
alitis (HSE). However, the disease is not caused by herpes
simplex virus (HSV) infection or a paraneoplastic disease process.
Many previously reported patients with NHALE had a rather
favorable neurological prognosis compared to those with HSE
[2,4]. There have been a few reports on the autopsy cases with
NHALE [4,5]. These reports demonstrated that there were neuronal
loss and severe gliosis with inﬂammatory cell inﬁltrations in the
hippocampus and amygdala. The pathogenesis of NHALE is still
unclear.
To investigate the immunological pathogenesis of NHALE, we
determined the cerebrospinal ﬂuid (CSF) concentrations of
interferon-c (IFN-c), tumor necrosis factor-a (TNF-a), interleu-
kin-2 (IL-2), IL-4, IL-6, IL-10, and soluble TNF receptor 1 (sTNFR1)
as cytokines related to inﬂammation in patients with NHALE and
HSE.ll rights reserved.
hiyama).2. Patients and methods
Informed consent was obtained from the families of the patients
and controls enrolled in this study.2.1. NHALE
CSF samples were obtained from 15 patients with NHALE (ﬁve
males and 10 females, aged from 12 to 82 years; median, 35
years) admitted to Yamaguchi University Hospital and seven col-
laborating research hospitals from July 1999 to February 2008
(Tables 1 and 2). The criteria for the diagnosis of NHALE were:
(1) acute or subacute onset neurological disorder with limbic-
associated symptoms, such as amnesia, delirium, panic, anxiety,
excitation, etc., (2) negative HSV DNA in CSF by the nested poly-
merase chain reaction (PCR) and negative HSV antibodies in CSF
determined by the enzyme-linked immunosorbent assay (ELISA),
(3) lesions of the temporal lobe, especially hippocampi and amy-
gdalae, on magnetic resonance imaging (MRI) (Fig. 1), (4) absence
of malignancy, (5) no bacteria or fungi in CSF culture, and (6) the
exclusion of all other neurological, vascular, metabolic, endocrine,
toxic, and drug-induced disorders. CSF samples obtained during
the acute stage were stored at 70 C.
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CSF samples were obtained from 13 patients with HSE (eight
males and ﬁve females, aged from 13 to 76 years; median, 61
years) admitted to Yamaguchi University Hospital and two collab-
orating research hospitals from October 2000 to December 2005
(Table 1). The diagnosis was based on the demonstration of HSV
DNA in the CSF by nested PCR. CSF samples during acute stage
were stored at 70 C.
2.3. Control subjects
The control subjects for the CSF levels of the cytokines were 19
afebrile and non-infectious patients with neurological disorders,
such as epilepsy, dementia, etc. (11 males and eight females, aged
from 13 to 79 years; median, 55 years), as shown in Table 1. CSF
samples were obtained from them on routine analysis and they
all had normal CSF cell counts.
2.4. Clinical data
The clinical data including age, gender, clinical symptoms on
admission, CSF ﬁndings at the time of specimen collection,MRI ﬁnd-
ings during the acute stage, and clinical outcomes in patients with
NHALE and HSE were investigated. The outcomes were deﬁned as
follows: (1) normal resolution, (2)mild sequelae, (3) severe sequelae
necessitating help with daily life activities, and (4) death [6].
2.5. Determination of cytokine concentrations
The concentrations of CSF IFN-c, TNF-a, IL-2, IL-4, IL-6, and
IL-10 were measured with a cytometric bead array (CBA) kitTable 1
Clinical data of patients with NHALE, HSE, and controls
NHALE
N = 15
HSE
N = 13
Control subjects
N = 19
Age (median, range) 35 yr,
11–82 yr
61 yr,
13–76 yr
55 yr,
13–79 yr
Sex (male: female) 5:10 8:5 11:8
Comorbid conditions — — Epilepsy, 9;
dementia, 5;
psychosis, 4; Tic, 1
Prognosis Normal, 6;
mild
sequelae, 9
Mild sequelae, 5;
severe sequelae, 7;
death, 1
—
NHALE, non-herpetic acute limbic encephalitis; HSE, herpes simplex encephalitis.
Table 2
Clinical characteristics of the 15 patients with non-herpetic acute limbic encephalitis
No./age/gender Main symptoms on admission Lesions on MRI
1/34 yr/M Amnesia, delirium Bilateral temporal lobes
2/73 yr/F Somnolence, convulsion Bilateral temporal lobes
3/35 yr/M Amnesia, convulsion Bilateral temporal lobes
4/11 yr/M Convulsion, delirium Right temporal lobe
5/18 yr/F Convulsion Bilateral temporal lobes
6/49 yr/F Amnesia, convulsion Bilateral temporal lobes
7/31 yr/F Convulsion Bilateral temporal lobes
8/47 yr/F Insomnia, convulsion Bilateral temporal lobes
9/82 yr/F Amnesia, fugue Bilateral temporal lobes
10/67 yr/M Convulsion, delirium Bilateral temporal lobes
11/75 yr/F Convulsion, enuresis Bilateral temporal lobes
12/51 yr/M Amnesia, convulsion Bilateral temporal lobes
13/14 yr/F Panic Left temporal lobe
14/19 yr/F Excitation, convulsion Bilateral temporal lobes
15/12 yr/F Anxiety, insomnia Bilateral temporal lobes(BD PharMingen, San Diego, CA, USA) according to the manufac-
turer’s manual, as previously described [7–9], with modiﬁcation
of the data analysis using GraphPad Prism software (GraphPad
Prism Software, San Diego, CA, USA). Brieﬂy, each series of beads
exhibiting discrete ﬂuorescence intensities is coated with a
monoclonal antibody against a single cytokine, and a mixture
of six series of beads can detect six cytokines in one sample. A
secondary phycoerythrin-conjugated monoclonal antibody stains
the beads proportionally to the amount of bound cytokine. After
ﬂuorescence intensity calibration and electronic color compensa-
tion procedures, standard and test samples were analyzed with a
FACScan ﬂow cytometer equipped with CellQuest software (BD
PharMingen). The lower detection limits for IFN-c, TNF-a, IL-2,
IL-4, IL-6, and IL-10 were 7.1, 2.8, 2.6, 2.6, 2.5, and 2.8 pg/ml,
respectively.
The CSF concentrations of sTNFR1 were determined with a
sTNFR1 ELISA kit (Bender Medsystems, Vienna, Austria), as de-
scribed previously [10]. The lower detection limit for sTNFR1 was
0.05 ng/ml.
2.6. Statistical analysis
All data were log transformed to obtain an approximately nor-
mal distribution. The differences in the results between groups
were analyzed with a t-test and the v2 test, and those with a p-va-
lue of less than 0.05 were considered signiﬁcant. Correlations were
analyzed using Pearson’s coefﬁcient correlation. Analyses and cal-
culations were performed using SPSS-12.0 (SPSS, Inc., Chicago, IL,
USA).3. Results
3.1. Clinical characteristics
Clinical data of patients with NHALE are shown in Tables 1 and
2. There were no signiﬁcant differences in age or gender among pa-
tients with NHALE and HSE and controls (median age, 35, 61, and
55 years, respectively). The CSF cell counts of patients with NHALE
were lower than those with HSE (p = 0.015, 9/ll vs. 32/ll as a med-
ian). The CSF protein levels of patients with NHALE were less than
those with HSE (p = 0.003, 33 vs. 50 mg/dl as a median). Of the 15
patients with NHALE, 9 (67%) had mild sequelae and 6 (33%) sur-
vived without sequelae. Of the 13 patients with HSE, 1 (8%) died
and 12 (92%) experienced disability (54% had severe and 38% had
mild sequelae).CSF ﬁndings Neurological prognosis
Cell (ll) Protein (mg/dl)
12 39 Normal
32 24 Normal
9 39 Mild amnesia
187 33 Intellectual impairment
39 31 Normal
42 50 Amnesia, psychopathy
0 27 Epilepsy
9 47 Normal
1 39 Amnesia
1 35 Amnesia
0 32 Amnesia, psychopathy
0 28 Amnesia
121 27 Normal
8 48 Intellectual impairment, epilepsy
14 25 Normal
Fig. 1. FLAIR MRI of Patient 2 (A), Patient 6 (B), and Patient 9 (C) demonstrated high signal intensity lesions in the bilateral temporal lobes.
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In patients with NHALE, the CSF concentrations of IL-6 were sig-
niﬁcantly higher than those of controls (p < 0.001), but those of
IFN-c, TNF-a, IL-2, IL-4, IL-10, or sTNFR1 were not (Fig. 2).
In patients with HSE, the CSF concentrations of IFN-c, IL-6, IL-
10, and sTNFR1 were signiﬁcantly higher than those of controls
(p = 0.004, p < 0.001, p = 0.018, and p < 0.001, respectively), but
those of TNF-a, IL-2, or IL-4 were not (Fig. 2). There were signiﬁ-
cant correlations among CSF IL-6, IL-10, and sTNFR1 levels in HSE
patients (IL-6 and IL-10, p = 0.008; IL-6 and sTNFR1, p < 0.001; IL-
10 and sTNFR1, p = 0.030) (Fig. 3).
The CSF concentrations of IFN-c and sTNFR1 levels of patients
with HSE were signiﬁcantly higher than those with NHALE
(p = 0.001, and p = 0.002, respectively) (Fig. 2).
4. Discussion
Main lesions in NHALE were in the bilateral temporal lobes,
especially the hippocampus and amygdala, similar to those in
HSE. However, HSV DNA or anti-HSV antibodies were not detectedFig. 2. The CSF concentrations of IFN-c, IL-6, IL-10, and sTNFR1 in patients with NHALE,
values below the detection limits.in the CSF of patients with NHALE. Previous reports on autopsy
cases of NHALE revealed that HSV-1 or -2 were not detected in
the brain [4,5]. Therefore, NHALE has been identiﬁed as a new type
of encephalitis, especially in Japan [1–4]. Several autoantibodies,
including those against the N-methyl-D-aspartate glutamate recep-
tor and voltage-gated potassium channel, were detected in pa-
tients with NHALE [4,11–14]. Moreover, patients with limbic
encephalitis associated with autoimmune disease, including
Hashimoto’s disease, Sjögren’s syndrome, and systemic lupus ery-
thematosus, have been reported [15–17]. These previous studies
suggest that NHALE is immune-mediated encephalitis.
The clinical outcomes of patients with NHALE were relatively
favorable compared with those with HSE. Moreover, CSF cell
counts and protein concentrations of patients with NHALE were
signiﬁcantly less and lower than those with HSE, suggesting that
inﬂammation in the CNS in NHALE is milder than that in HSE. In
this study, we demonstrated CSF cytokine proﬁles of NHALE com-
pared with HSE. In patients with NHALE, the CSF concentrations of
IL-6 were signiﬁcantly higher than those of controls, but those of
IFN-c, TNF-a, IL-2, IL-4, IL-10, or sTNFR1 were not. IL-6 is well-
known as a cytokine that plays important roles in inﬂammatory re-HSE, and controls. Horizontal lines indicate geometric means. Shaded areas indicate
Fig. 3. The relationship among CSF IL-6, IL-10, and sTNFR1 concentrations in patients with HSE. r, Pearson’s coefﬁcient.
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inﬂammation modiﬁed by IL-6 in the central nervous system
(CNS). IFN-c, which is produced by NK cells and CD8+ and Th1 type
CD4+ T lymphocytes, plays an important role in host defense
against viral infection, and inhibits viral replication [20]. We previ-
ously demonstrated that CSF IFN-c levels were elevated in CNS dis-
orders due to direct viral invasion, such as viral meningitis and HSE
[2,21,22], but not in immune-mediated CNS disorders, such as
acute disseminated encephalomyelitis, inﬂuenza-associated
encephalopathy, acute encephalopathy following prolonged febrile
seizures, and hemolytic uremic syndrome with encephalopathy
[23–26]. Taking our ﬁndings into consideration, NHALE without
elevated IFN-c levels in the CSF in this study is not caused by direct
viral infection.
In patients with HSE, the CSF concentrations of IFN-c, IL-6, IL-
10, and sTNFR1 were signiﬁcantly higher than those with controls.
Our present data that CSF IFN-c levels were elevated in HSE were
consistent with a previous study [2]. There were signiﬁcant corre-
lations among CSF IL-6, IL-10, and sTNFR1 levels in HSE patients. In
addition, CSF sTNFR1 levels in HSE were signiﬁcantly higher than
those in NHALE. TNF-a increases blood–brain vascular permeabil-
ity, injures vascular endothelial cells, and induces the necrosis of
myelin and oligodendrocytes [29–31]. Previous studies have sug-
gested that TNF-a mediates the pathogenesis of acute encephali-
tis/encephalopathy [23,32–35]. It is believed that sTNFR reﬂects
the true biological activity of TNF-a [36–38]. CSF sTNFR1 levels
are related to the neurological prognosis in bacterial meningitis
and acute encephalopathy/encephalitis [10,33]. CSF sTNFR1 levels
may reﬂect the neurological outcome in HSE. IL-10 as an anti-
inﬂammatory cytokine decreases the production of IL-1, IL-6, and
TNF-a induced by an endotoxin or bacteria [27,28]. Therefore we
suggest that IL-10 is induced in the CNS to modulate pro-inﬂam-
matory cytokine-mediated inﬂammation in the CNS of patients
with HSE. Patients with HSE showed elevated pro-inﬂammatory
and anti-inﬂammatory cytokines in the CSF, suggesting that there
was severe inﬂammation in the CNS of these patients.
In conclusion, the CSF concentrations of IL-6 in patients with
NHALE and IFN-c, IL-6, IL-10, and sTNFR1 in HSE patients were sig-
niﬁcantly higher than those in controls. Patients with HSE had
many elevated cytokines in the CSF, but those with NHALE showed
only an elevated CSF level of IL-6. These ﬁndings may be related to
the fact that the clinical outcome of NHALE is relatively favorable
compared with that of HSE.Acknowledgments
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